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ABSTRACT
The University of Pittsburgh Molecular Library Screening Center 
(Pittsburgh, PA) conducted a screen with the National Institutes of 
Health compound library for inhibitors of in vitro cell division cycle 
25 protein (Cdc25) B activity during the pilot phase of the Molecu-
lar Library Screening Center Network.  Seventy-nine (0.12%) of the 
65,239 compounds screened at 10 μM met the active criterion of 
≥50% inhibition of Cdc25B activity, and 25 (31.6%) of these were 
confirmed as Cdc25B inhibitors with 50% inhibitory concentration 
(IC50) values <50 μM.  Thirteen of the Cdc25B inhibitors were repre-
sented by singleton chemical structures, and 12 were divided among 
four clusters of related structures.  Thirteen (52%) of the Cdc25B 
inhibitor hits were quinone-based structures.  The Cdc25B inhibitors 
were further characterized in a series of in vitro secondary assays 
to confirm their activity, to determine their phosphatase selectivity 
against two other dual-specificity phosphatases, mitogen-activated 
protein kinase phosphatase (MKP)-1 and MKP-3, and to examine if 
the mechanism of Cdc25B inhibition involved oxidation and inactiva-
tion.  Nine Cdc25B inhibitors did not appear to affect Cdc25B through 
a mechanism involving oxidation because they did not generate de-
tectable amounts of H2O2 in the presence of dithiothreitol, and their 
Cdc25B IC50 values were not significantly affected by exchanging the 
dithiothreitol for β-mercaptoethanol or reduced glutathione or by add-
ing catalase to the assay.  Six of the nonoxidative hits were selective 
for Cdc25B inhibition versus MKP-1 and MKP-3, but only the two bis-
furan-containing hits, PubChem substance identifiers 4258795 and 
4260465, significantly inhibited the growth of human MBA-MD-435 
breast and PC-3 prostate cancer cell lines.  To confirm the structure 
and biological activity of 4260465, the compound was resynthesized 
along with two analogs.  Neither of the substitutions to the two ana-
logs was tolerated, and only the resynthesized hit 26683752 inhibited 
Cdc25B activity in vitro (IC50 = 13.83 ± 1.0 µM) and significantly 
inhibited the growth of the MBA-MD-435 breast and PC-3 prostate 
cancer cell lines (IC50 = 20.16 ± 2.0 μM and 24.87 ± 2.25 µM, re-
spectively).  The two bis-furan-containing hits identified in the screen 
represent novel nonoxidative Cdc25B inhibitor chemotypes that block 
tumor cell proliferation.  The availability of non–redox active Cdc25B 
inhibitors should provide valuable tools to explore the inhibition of 
the Cdc25 phosphatases as potential mono- or combination therapies 
for cancer.
INTRODUCTION
he critical roles that the three human cell division cycle 25 
proteins (Cdc25s) (A, B, and C) play in the regulation of 
the cell cycle and DNA damage-activated checkpoints make 
them attractive targets for the development of antiprolifera-
tive cancer drugs.1–5  The Cdc25s are dual-specificity phosphatases 
that dephosphorylate threonine and tyrosine residues (T14 and Y15) 
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on cyclin-dependent kinases (CDKs), thereby activating the CDK–
cyclin complexes, which regulate progression through the cell cy-
cle.1,6  Historically, specific Cdc25 isoforms have been ascribed to the 
regulation of distinct transition phases of the mammalian cell cycle: 
Cdc25A was thought to primarily activate CDK1–cyclin E and CDK2–
cyclin A complexes during the G1-S transition, while Cdc25B and 
Cdc25C were believed to preferentially activate CDK1–cyclin B com-
plexes during the G2-M transition.1–3,5,6  It is now believed that all three 
Cdc25 isoforms cooperate to play essential roles in the temporal and 
spatial regulation of the CDKs during all stages of the cell cycle.1–3,6 
In response to DNA damage cells activate checkpoint signaling path-
ways that lead to a transient cell cycle arrest, which is maintained 
until either the DNA is repaired or the cell undergoes apoptosis.1–3,5,6 
The proximal ataxia telangiestasia mutated and ataxia-telangiestasia-
and-RAD3-related kinases recognize DNA damage and trigger sig-
naling cascades that activate the checkpoint effector kinases (CHKs) 1 
and 2, which in turn modulate the activity of other cellular proteins 
including inactivation of the Cdc25 phosphatases.1–3,5,7,8  Inactivation 
of the Cdc25s is achieved through CHK1/CHK2 phosphorylation of 
specific residues that regulate the proteasome-mediated degradation 
of Cdc25s, Cdc25 catalytic activity, or interactions between Cdc25s 
and 14-3-3 family members that sequester the Cdc25s in the cyto-
plasm away from their substrates.1–3,5,7,8  Cdc25 inactivation produces 
either a G1 or G2 arrest that is dictated by the nature of the stressor, 
the type of DNA damage induced, and the signaling pathway that is 
activated.1–3,5,7,8  DNA damage checkpoints serve to maintain genetic 
integrity by preventing cells with damaged DNA from dividing and 
allowing DNA repair to occur.1–3,5,7,8  In noncancerous cells, irrepara-
bly damaged cells undergo apoptosis, thereby eliminating them from 
the pool of replicating cells.1–3,5,7,8
Cdc25s have been linked to oncogenic transformation in mice, 
and elevated expression of Cdc25A and Cdc25B at the mRNA and/
or protein levels has been reported in a wide variety of primary 
human tumor samples.1,2,5  Enhanced expression of Cdc25A and 
Cdc25B in tumors correlates with specific clinical and pathological 
features: higher-grade or later-stage tumors, more aggressive tu-
mors, and a shorter disease-free survival.1,2,5  Increased phosphatase 
activity resulting from the higher expression of Cdc25A and Cdc25B 
in tumor cells may contribute to unregulated proliferation through 
the overactivation of CDK–cyclin complexes that inappropriately 
drive cells through the cell cycle.1,2,5  Inappropriate and accelerated 
entry into S phase and/or the initiation of mitosis with incompletely 
replicated DNA may also lead to the accumulation of genetic aber-
rations and tumorigenesis.1,2,5  In normal cells DNA damage check-
point activation induces degradation and/or inactivation of Cdc25s 
and cell cycle arrest.1,2,5,7,8  However, the increased expression of 
Cdc25A and Cdc25B in tumor cells may overwhelm the inactivation 
machinery, and the continued activation of CDK–cyclin complexes 
could conceivably push through the checkpoint barrier before the 
damaged DNA has been repaired, again contributing to genetic in-
stability and malignant transformation.1,2,8
Entry into mitosis is initiated by the activation of the CDK1–cyclin 
B complex, which is maintained in its inactive form by Wee1 and 
Myt1 kinase-mediated phosphorylation of the Thr14 and Tyr15 resi-
dues of CDK1.1,2,5,8–10  During prophase, active CDK1–cyclin B com-
plexes first appear on centrosomes and subsequently translocate 
into the nucleus.7,8  Cdc25B accumulates from late S phase through 
early G2, and its activity peaks during the G2-M transition when 
it functions to initiate mitosis by dephosphorylating and activating 
CDK1–cyclin B complexes on centrosomes, thus triggering spindle 
formation.7,8  The nuclear import of CDK1–cyclin B complexes and 
the subsequent stabilization of Cdc25C lead to chromatin condensa-
tion and the onset of mitosis.7,8  Ectopic overexpression of Cdc25B 
produced both chromatin aberrations and multipolar spindle pheno-
types.7–9  Once DNA damage has been repaired, the DNA damage 
checkpoint is silenced so that cell cycle progression may resume.7–9 
The resumption of the cell cycle after G2-M arrest has been shown to 
depend upon both Cdc25B and polo-like-kinase activities.7–12  Mech-
anistically distinct DNA-damaging agents induce a rapid increase in 
Cdc25B levels, and the extent of protein expression influence the ki-
netics of cell cycle resumption after DNA damage-induced arrest.11,12 
Increased levels of Cdc25B, produced by ectopic overexpression or 
by constitutive expression in cancer cells, permit cells to bypass the 
DNA damaging agent-induced G2-M checkpoint arrest and prema-
turely enter mitosis.9  The inappropriate re-initiation of mitosis after 
genotoxic-induced G2-M checkpoint arrest in tumor cells with in-
creased Cdc25B expression could reduce the therapeutic efficacy of 
DNA-damaging agents and further the propagation of genetic defects 
to daughter cells that may contribute to tumor growth.1,2,5,6  Cdc25B 
inhibitors therefore have potential as combination anticancer therapy 
because they should impair checkpoint recovery and likely produce a 
more pronounced G2 arrest in response to DNA-damaging drugs that 
could lead to increased apoptosis and better efficacy.1,2,5,6
The University of Pittsburgh Molecular Library Screening Center 
(PMLSC) (Pittsburgh, PA) accepted a project to screen the National 
Institutes of Health (NIH) compound library for inhibitors of in vi-
tro Cdc25B activity during the pilot phase of the Molecular Library 
Screening Center Network (MLSCN).13–18  We present here the results 
of that screening campaign and the subsequent follow-up hit char-
acterization of the Cdc25B inhibitors that were identified.
MATERIALS AND METHODS
Reagents and Supplies
Trizma, dithiothreitol (DTT), β-mercaptoethanol (BME), reduced 
glutathione (GSH), tris(2-carboxyethyl)phosphine  (TCEP), H2O2 
(30% wt/wt), phenol red, horseradish peroxidase (HRP), catalase 
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(CAT), and 3-O-methylfluorescein phosphate (OMFP) were pur-
chased from Sigma-Aldrich Co. (St. Louis, MO).  Sodium chloride 
was from VWR (West Chester, PA). EDTA and sodium hydroxide 
were from EMD (Gibbstown, NJ).  Bovine serum albumin was from 
Invitrogen (Carlsbad, CA).  Dimethyl sulfoxide (DMSO) (99.9% high-
performance liquid chromatography-grade, under argon) was from 
Alfa Aesar (Ward Hill, MA). All other materials were reagent grade.
Cdc25B, Mitogen-Activated Protein Kinase Phosphatase 
(MKP)-1, and MKP-3 Protein Expression and Purification
The expression and purification of an epitope-tagged (hexahis-
tidine) recombinant Cdc25B catalytic domain, MKP-1, and MKP-3 
have been described previously.19  In brief, His-tagged Cdc25B, 
MKP-1, and MKP-1 were expressed in BL21(DE3) competent bacte-
rial cells transformed with the appropriate pET expression vectors 
encoding the required phosphatase and induced with isopropyl-β-
D-thiogalactopyranoside.  Biologically active phosphatase was par-
tially purified from isopropyl-β-D-thiogalactopyranoside-induced 
bacterial cell lysates by cobalt-column chromatography eluted 
with imidazole, frozen, aliquoted, and stored at –80°C.  The relative 
purity of the phosphatase enzyme preparation was visualized by 
separating the protein components by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and staining with Coomassie Brilliant 
Blue.  The identity of the phosphatase enzyme was confirmed by 
the presence of a protein band with the anticipated relative mobility 
in sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels 
together with immunoreactivity with antibodies against the specific 
phosphatase and the His-tag epitope on western blots.
Compound Library
The NIH library of 65,239 compounds was formatted at 10 mM con-
centration in DMSO, arrayed into 384-well microtiter master plates, 
and distributed to the PMLSC by the small molecule repository Biofo-
cus-DPI (A Galapagos Company, San Francisco, CA).13,14,16,17,20  Com-
pounds were identified by their PubChem substance identity numbers 
(SIDs).  Daughter plates containing 2 µl of 1 mM compounds in DMSO 
were prepared and replicated from the MLSCN master plates using the 
Velocity11 (Menlo Park, CA) Vprep® outfitted with a 384-well transfer 
head.  Aluminum adhesive plate seals were applied with an ABgene 
(Rochester, NY) plate sealer, and plates were stored at -20°C in a Ma-
trical (Spokane, WA) MatriMinistore™ automated compound storage 
and retrieval system.  Immediately prior to use daughter plates were 
withdrawn from -20°C storage, thawed at ambient temperature, and 
centrifuged 1–2 min at 50 g, and the plate seals were removed prior 
to the transfer of the appropriate volume of deionized H2O to ensure a 
concentration of the library compounds of 30 μM (in 3% DMSO) us-
ing the Velocity11 Vprep outfitted with a 384-well transfer head.  The 
diluted compounds were mixed by repeated aspiration and dispensing 
using the 384-well transfer head of the Velocity11 Vprep, and 5 µl was 
transferred to the compound wells of assay plates.
Cdc25B, MKP-1, and MKP-3 Phosphatase Assays
The development and optimization of 384-well-format low-vol-
ume homogeneous fluorescence intensity assays for Cdc25B, MKP-1, 
and MKP-3 have been described previously.16,19  In brief, the assay 
involved three consecutive 5-µl additions to low-volume microtiter 
plates (catalog number 784076, Greiner BioOne, (Monroe, NC)  per-
formed on either the Velocity11 Vprep or the Evolution P3™ (Perki-
nElmer, Waltham, MA) automated liquid handler outfitted with a 
384-well transfer head, plate controls and compounds,  phosphatase 
enzyme, and OMFP substrate.  Compounds were individually tested 
at 10 µM in the Cdc25B primary screen in an assay buffer compris-
ing 30 mM Tris (pH 8.0), 75 mM NaCl, and 1.0 mM EDTA, at a final 
DMSO concentration of 2%, with 1% each contributed by the diluted 
compounds and OMFP substrate.  For the MKP-1 and MKP-3 assays 
the pH of the assay buffer was 7.0 rather than 8.0 to ensure optimal 
enzyme activity.16,19  The phosphatase reactions were terminated after 
a 60-min incubation at ambient temperature by a 5-µl addition of 
either 2 mM Na3VO4 in deionized H2O for Cdc25B or 500 mM NaOH 
in deionized H2O for MKP-1 and MKP-3,
16,19 performed on the Veloci-
ty11 Vprep outfitted with a 384-well transfer head.  The fluorescence 
intensity of OMF product was measured on a Molecular Devices 
(Sunnyvale, CA) SpectraMax M5 plate reader (excitation filter, 485 
nm; emission filter, 525 nm; auto cutoff, 515 nm).
For concentration–response confirmation and hit characterization 
assays, compounds were tested in singleton 10-point twofold dilution 
series concentration–response assays, starting at a maximum final 
concentration of 50 µM (2% DMSO).  Compounds were diluted to 150 
µM in deionized H2O (3% DMSO final concentration) and serially di-
luted in deionized H2O and 3% DMSO to provide the desired concen-
tration range.  Five microliters of the compound dilutions was trans-
ferred to a total assay volume of 15 µl (threefold dilution) performed 
on the Velocity11 Vprep outfitted with a 384-well transfer head.
Cdc25B Inhibitor Hit Characterization
Cdc25B inhibitors that were confirmed in concentration–response 
assays were tested for phosphatase selectivity against MKP-1 and 
MKP-3 in singleton 10-point twofold dilution series concentration–
response assays, starting at a maximum final concentration of 50 µM 
as described above.  To identify Cdc25B inhibitors that might be in-
activating the enzyme through a mechanism involving oxidation and 
inactivation,21 we modified various components of the primary Cd-
c25B assay described above and determined if they  either abolished 
the inhibition of Cdc25B or significantly shifted the potencies of the 
Cdc25B 50% inhibitory concentration (IC50) values higher  (Table 1). 
In two of the Cdc25B hit characterization assays the 1 mM DTT 
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 reducing agent used in the HTS was replaced with either 1 mM BME 
or 1 mM GSH.  In other Cdc25B formats, 100 U of CAT was added to 
the assay to degrade H2O2, the DTT concentration was increased from 
1 mM to 25 mM, or reactions were conducted in the presence of both 
100 U of CAT and 25 mM DTT.
384-Well Redox Cycling H2O2 Generation Assay
The H2O2 generation assay was performed in 384-well flat-bottomed 
clear polystyrene microtiter plates with a well volume of 120 μl (cat-
alog number 781101, Greiner BioOne) as described previously.15  Com-
pounds and plate controls were diluted to the required concentrations 
in Hanks’ Balanced Salt Solution.  Plate controls were represented by 
100 μM H2O2 (maximum, n = 32) or 1% DMSO (minimum, n = 24) (fi-
nal concentrations) in the well.  DTT was diluted in Hanks’ Balanced 
Salt Solution from 200 mM stocks to the required concentrations (typ-
ically 0.5–1.0 mM final concentration in the well).  The phenol red-
HRP detection reagent contains 300 μg/ml phenol red and 180 μg/ml 
HRP in Hanks’ Balanced Salt Solution.  The assay involved three liquid 
Table 1. Cdc25B Inhibitor Hit Characterization
SID
AID 368
HTS (% 
inhibition)
IC50 (µM) for AID in assay
AC50 (µM) for AID 
in assay
569
CFM
650
HCF
674
MKP-1
673
MKP-3
670
BME
671
GSH
668
CAT
649
25D
669
CAT 25D
682
H2O2 
0.5D
683
H2O2 
1.0D
850758 100.6 0.542 0.421 0.333 0.629 41.845 >50 >50 17.227 >50 0.646 1.046
845167 100.9 0.400 0.493 0.485 0.615 >50 >50 20.022 21.125 >50 0.731 1.605
4251194 101.8 0.349 0.551 0.423 0.433 32.365 35.510 23.000 34.529 >50 1.166 3.158
847359 100.4 13.538 20.375 >50 >50 >50 >50 >50 >50 >50 3.888 13.622
3712327 65.2 15.495 14.711 >50 >50 23.011 24.189 23.582 >50 >50 7.905 24.962
845964 101.7 0.949 0.502 2.379 2.739 33.080 42.970 14.055 49.271 >50 12.880 23.940
7973677 98.4 3.627 5.117 43.772 19.774 >50 >50 >50 >50 >50 13.158 41.370
3712249 101.2 5.252 1.410 14.647 3.707 > 50 > 50 > 50 > 50 > 50 13.172 27.490
856108 66.0 9.528 9.535 >50 >50 26.310 31.737 47.092 >50 >50 24.117 >50
8139964 99.0 13.113 12.171 >50 >50 20.380 24.974 25.398 >50 >50 25.648 > 50
857882 62.0 49.563 25.491 >50 >50 >50 >50 >50 >50 >50 26.104 45.673
4242461 96.4 4.306 4.934 > 50 48.661 >50 >50 >50 >50 >50 28.608 >50
4251929 85.4 3.276 2.220 10.678 12.599 >50 >50 45.752 47.983 >50 >50 >50
4249736 80.9 4.229 2.238 8.746 12.079 >50 >50 45.033 42.269 >50 >50 >50
4249621 63.4 9.099 3.117 4.606 >50 3.802 2.787 3.804 7.420 8.693 >50 >50
4241893 61.3 4.695 3.495 7.018 >50 1.783 2.133 4.197 14.673 16.784 >50 >50
844096 52.6 30.223 5.429 42.517 >50 4.198 4.729 7.115 17.712 20.486 >50 >50
850390 50.9 8.056 5.730 >50 >50 8.114 8.229 6.177 11.702 13.238 >50 >50
843791 51.4 5.852 5.984 >50 >50 5.197 5.891 7.351 11.390 12.062 >50 >50
7964733 58.6 24.131 6.275 >50 19.763 >50 >50 48.860 >50 >50 >50 >50
851514 55.6 13.939 7.097 >50 >50 7.420 6.761 11.000 12.813 16.013 >50 >50
847214 50.5 21.954 7.162 >50 >50 6.351 6.798 7.109 10.909 11.399 >50 >50
4260465 50.3 15.534 9.213 >50 >50 10.328 11.124 15.655 >50 >50 >50 >50
4258795 51.0 11.637 15.349 >50 >50 19.221 23.651 22.375 39.842 40.874 >50 >50
4248661 81.3 26.368 24.251 >50 >50 >50 >50 >50 >50 >50 >50 >50
CFM, confirmatory concentration–response assay; HCF, hit confirmation concentration–response assay; MKP-1, MKP-1 concentration–response assay; MKP-3, MKP-3 
concentration–response assay; BME, Cdc25B concentration–response assay conducted with BME; GSH, Cdc25B concentration–response assay conducted with GSH; CAT, 
Cdc25B concentration–response assay conducted in the presence of CAT; 25D, Cdc25B concentration–response assay conducted in the presence of 25 mM DTT; CAT 25D, 
Cdc25B concentration–response assay conducted in the presence of CAT and DTT; H2O2 0.5D, redox cycling H2O2 generation assay conducted in 0.5 mM DTT; H2O2 1.0D, redox 
cycling H2O2 generation assay conducted in the presence of 1.0 mM DTT.
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transfer steps into the 384-well plate performed on the Evolution P3 
liquid handling platform using a 384-well P30 dispensing head and 
20 μl each of compounds/controls, DTT, and the phenol red-HRP de-
tection reagent to give a final assay volume of 60 μl. Compounds and 
DTT were incubated together at ambient temperature for a minimum 
of 15 min before addition of the phenol red-HRP detection reagent 
(100 μg/ml phenol red and 60 μg/ml HRP final concentration in the 
well).  After an additional incubation 
period at ambient temperature, mini-
mally 5 min, the assay was terminated 
by addition of 10 µl of 1 N NaOH, and 
the absorbance of the phenol red was 
measured at 610 nm in a SpectraMax 
M5 microtiter plate reader.
MDA-MB-435 and PC-3 Growth 
Inhibition Assays
The proliferation of the human 
MBA-MD-435 breast and PC-3 prostate 
cancer cell lines was measured using 
a previously described high-content 
imaging assay.22  MBA-MD-435 and 
PC-3 cells were seeded at 2,000 cells 
per well in collagen-coated 384-well 
black-walled clear-bottom plates (cat-
alog number 781091, Greiner BioOne) 
and cultured for 2–72 h at 37°C in a 
5% CO2 atmosphere and 95% humidi-
ty. After a 2-h cell attachment period, 
one plate of cells was fixed, stained, 
and analyzed as described below to 
establish the cell density at the time of 
treatment; the other plates were treat-
ed with the indicated compound con-
centrations transferred to the 384-well 
plate on the Evolution P3 liquid han-
dling platform using a 384-well P30 
dispensing head and cultured for an 
additional 24–72 h.  At the indicat-
ed time points, plates were fixed with 
3.7% formaldehyde containing 2 µg/
ml Hoechst 33342 at 37°C for 10 min, 
the fixed cells were then washed twice 
with Dulbecco’s phosphate-buffered 
saline, and aluminum adhesive plate 
seals were applied with the ABgene 
plate sealer.  Images of the Hoechst-
stained nuclei from nine fields of 
view per well were acquired on an ArrayScan VTI imaging platform 
(Thermo Fisher Scientific, Pittsburgh, PA) using a 10× 0.3NA objec-
tive and the XF100 filter set.  Hoechst-stained nuclei were quanti-
fied using an image analysis algorithm that segmented the images 
and identified nuclear objects on the basis of total and average 
fluorescent intensity and size (area) and shape (width and length) 
thresholds.  The total number of selected objects (nuclei) from nine 
Fig. 1. Cdc25B high-throughput screen performance data. (A) Forty HTS plate overlay scatter plot of 
the percentage inhibition Cdc25B data from the third day of screening operations. An ActivityBase 
HTS template was written to calculate the percentage inhibition based on the maximum (n = 32) 
and minimum (n = 24) plate controls for the Cdc25B HTS campaign. A Spotfire visualization of the 
percentage inhibition data from 40 384-well plates of the Cdc25B HTS conducted on the third day 
of screening operations overlaid in a single scatter plot is presented: maximum (2% DMSO, n = 32) 
plate controls (?), minimum (500 μM Na
3
VO
4
 and 2% DMSO, n = 24) plate controls (?), 50% (500 
μM Na
3
VO
4 
and 2% DMSO, n = 8) plate controls (?), and 10 μM compounds (2% DMSO, n = 320) (+). 
(B) Plate controls Z’-factors for the Cdc25B HTS campaign. An ActivityBase HTS template was written 
to calculate Z’-factors for each plate based on the maximum (2% DMSO, n = 32) and minimum (500 
μM Na
3
VO
4
 and 2% DMSO) plate controls. The Cdc25B HTS campaign was conducted over 6 days 
of screening operations, and the associated plate Z’-factors for all 207 plates are plotted for each 
day: (?) day 1, (?) day 2, (?) day 3, (?) day 4, (?) day 5, (?) day 6. (C) Compound percentage 
inhibition frequency distribution for the Cdc25B HTS campaign. An ActivityBase HTS template was 
written to calculate the percentage inhibition, based on the mean maximum (2% DMSO, n = 32) and 
mean minimum (500 μM Na
3
VO
4
 and 2% DMSO, n = 24) plate controls, and the data were uploaded 
to an Oracle database. The percentage inhibition of Cdc25B for all compounds run in the screen was 
queried from the database and exported to Spotfire for visualization of the frequency distribution 
of the calculated results.
A
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fields of view covering the whole well provided the total cell count 
per well.  The extent of growth inhibition observed in compound-
treated wells is expressed as a percentage of the total cell counts in 
these wells relative to the total cell counts in DMSO control wells: % 
growth inhibition = ([mean total cell count in DMSO control wells 
– total cell count in treated wells] × 100)/mean total cell count in 
DMSO control wells.
Data Analysis: HTS and IC50 Values
We utilized GraphPad Software (La Jolla, CA) Prism® version 5.0 
software to plot and analyze assay development data and perform 
linear regression analysis, four-parametric nonlinear regression curve 
fitting, and enzyme kinetics analysis. To analyze the percentage in-
hibition of Cdc25B at 10 μM in the primary screen, we constructed 
an ActivityBase™ (IDBS, Guilford, UK) HTS template to calculate the 
percentage inhibition, based on the mean maximum (n = 32) and 
mean minimum (n = 24) plate controls, plate signal-to-background 
ratios (mean maximum signal/mean minimum signal), and Z-fac-
tors.23  The data were exported to Spotfire® (TIBCO, Somerville, MA) 
for visualization to help identify process errors and facilitate quality 
control analysis.  To analyze the Cdc25B inhibition, we constructed 
an ActivityBase concentration–response template to calculate per-
centage inhibition together with plate control signal-to-noise ratio 
and Z-factors for quality control purposes.  IC50 values were calcu-
lated using an XLfit four-parameter logistic model, also called the 
Sigmoidal Dose-Response Model: y = (A + ((B – A)/(1 + ((C/x)^D)))), 
where y is the percentage inhibition and x is the corresponding com-
pound concentration.  The fitted C parameter is the IC50, defined as 
the concentration giving a response halfway between the fitted top 
(B) and bottom (A) of the curve.  The fitted D parameter is called the 
“Slope” and equals the Hill coefficient.  The top parameter B was 
locked at 100%, and the bottom parameter A was set at 0%.
Compound Structure Clustering 
Analysis
Cdc25B inhibitors that were iden-
tified in the HTS and confirmed in 
10-point concentration–response IC50 
assays were analyzed using Lead-
scope® (Columbus, OH) Enterprise ver-
sion 2.4.6-1 software.  The active com-
pounds were subjected to structure-
based clustering and classification 
techniques based on recursive parti-
tioning24 as described previously.16,17
RESULTS
The PMLSC screened the NIH com-
pound library of 65,239 compounds 
against the Cdc25B assay in 6 days, 
and the Cdc25B primary HTS data 
from a single 40-plate day of op-
erations together with the plate Z’-
factors, signal-to-background ratios, 
and percentage inhibition frequency 
B
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distribution from the entire HTS campaign are presented in Fig. 1. 
The 40-plate overlay of the percentage inhibition of Cdc25B data 
from a single day of screening operations (Fig. 1A) demonstrates 
that the assay plate controls and corresponding assay signal win-
dow performed consistently and reproducibly, that the majority of 
compounds did not inhibit Cdc25B, and that an acceptable number 
of compounds (0.12% overall for the HTS) met the active criterion of 
≥50% inhibition of Cdc25B activity (Fig. 1A).  Overall, the Cdc25B 
HTS of the 65,239 compound library performed extremely well and 
exhibited a mean Z’-factor of 0.76 ± 0.09 with only two of the 207 
plates producing Z’-factors below 0.5 (Fig. 1B).  The frequency dis-
tribution of the percentage inhibition 
of Cdc25B for the screen approximates 
a normal distribution in which the 
majority of compounds were inactive 
(Fig. 1C), and only 79 (0.12%) of the 
65,239 compounds screened achieved 
the active criterion of ≥50% inhibition 
of Cdc25B activity at 10 μM.
 The active compounds identified in 
the Cdc25B primary HTS were cher-
ry-picked by the NIH small molecule 
repository, and 25 (31.6%) of the 79 
active compounds were confirmed as 
concentration-dependent Cdc25B in-
hibitors (Fig. 2 and Table 1, PubChem 
assay identifier [AID] 569, confirma-
tory concentration–response assay). 
The 25 confirmed Cdc25B inhibitors 
exhibited IC50 values in the following 
ranges: four were <1.0 μM, 10 were 
between 1.0 and 10.0 μM, and 11 were between 10.0 and 50.0 μM 
(Table 1, AID 569).  Thirteen of the confirmed Cdc25B inhibitors 
were represented by singleton chemical structures, and their IC50 
values ranged between 1.0 and 50.0 μM (Fig. 2A).  The remaining 
12 confirmed Cdc25B inhibitors were divided among four clusters 
with related structures with IC50 values ranging between 400 nM 
and 50.0 μM: two benzamides, five cyclopenta[c]quinoline-carbox-
ylic acids, three pyrimido[5,6-e][1,2,4]triazine-5,7-diones, and two 
phenyl-amino-2H-isoquinolin-1-ones (Fig. 2B).
The Cdc25B inhibitor hits were then further characterized in a 
series of in vitro secondary assays to confirm their Cdc25B activity 
Fig. 2. Compound structures and IC
50
 
values for Cdc25B inhibitors confirmed 
in 10-point concentration dependence 
assays: (A) singletons and (B) clusters. 
Cdc25B inhibitors that were identified 
in the HTS and confirmed in 10-point 
dose–response IC
50
 assays were ana-
lyzed using the Leadscope Enterprise 
version 2.4.6-1 software. The active 
compounds were subjected to struc-
ture-based clustering and classification 
techniques based on recursive parti-
tioning that produced singleton struc-
tures and clusters of related structures. 
The PubChem SIDs, Cdc25B IC
50
 values 
(in μM), chemical structures, and names 
of the chemical clusters are presented.
A
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(AID 650, hit confirmation concentration–response assay), to de-
termine their phosphatase selectivity against MKP-1 (AID 674) and 
MKP-3 (AID 673), to examine whether they might be inhibiting Cd-
c25B through a mechanism involving oxidation and inactivation21 
(AIDs 670, 671, 668, 649, and 669), and to test their activity in the 
redox cycling H2O2 generation assay
15
 (AIDs 682 and 683) (Table 1).  
The 25 confirmed Cdc25B inhibitors (AID 569) consistently inhib-
ited Cdc25B with IC50 values <26 μM (AID 650); as shown under 
AIDs 674 and 673, 12 appeared to be selective for Cdc25B, three 
also inhibited MKP-1, two also inhibited MKP-3, and eight inhibited 
all three dual-specificity phosphatases (Table 1).  Twelve of the 25 
Cdc25B inhibitors gave 50% activation concentration (AC50) values 
for H2O2 generation in the presence of 0.5 mM DTT (AID 682), and 
nine of these also produced AC50 values in the presence of 1.0 mM 
DTT (AID 683) (Table 1).  Two additional compounds, the phenylami-
no-2H-isoquinolin-1-ones, SIDs 4251929 and 4249736, did not pro-
duce an AC50 in either of these redox cycling assays but reproducibly 
achieved between 10% to 20% activation at 50 μM (data not shown) 
and should therefore be considered capable of redox cycling.  For 
the 14 compounds that exhibited activity in one or both of the re-
dox cycling assays, their Cdc25B IC50 values were either abolished 
or significantly increased by exchanging the DTT for BME (AID 
670) or GSH (AID 671), by add-
ing CAT to the assay (AID 668), 
and/or by raising the DTT con-
centration to 25 mM (AIDs 649 
and 669) (Table 1).  Although 
two quinone-based compounds 
(SIDs 7964733 and 4248661) 
failed to produce detectable 
amounts of H2O2 in the presence 
of DTT, their Cdc25B IC50 values 
were either abolished or signifi-
cantly increased by the indicat-
ed modifications to the Cdc25B 
assay (Table 1).  Six of the nine 
non–redox active compounds 
that were active in the Cdc25B 
primary HTS (AID 368) and both 
the confirmation (AID 569) and 
hit characterization (AID 650) 
concentration–response assays 
appeared to be selective Cd-
c25B inhibitors since they did 
not significantly inhibit either 
MKP-1 or MKP-3 at ≤50 µM 
(Table 1).  Three of the non–
redox active Cdc25B inhibitors 
are from the cyclopenta[c]quin-
oline-carboxylic acid cluster of 
hits (SIDs 843791, 850390, and 
851514), and the other three 
(SIDs 4258795, 4260465, and 
847214) were represented by 
singleton chemical structures 
(Fig. 2).
A cross-target query of the 
PubChem database revealed 
that the six Cdc25B inhibitors 
B
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had been tested in between 192 and 227 assays uploaded to Pub-
Chem and on average had produced active flags in 10.7% of those 
assays (Table 2).  SID 4258795 exhibited confirmed activity against 
13 different targets, whereas the other five Cdc25B inhibitors have 
only been confirmed active against a relatively small number of 
other targets (Table 2).  To date, SID 847214 has only been con-
firmed as an inhibitor of Cdc25B and the antigen receptor-induced 
activation of nuclear factor κB (Table 2).  However, the other four 
Cdc25B inhibitors have exhibited confirmed activity against four 
to seven other targets, including three common targets:  hydroxys-
teroid 17β-dehydrogenase 4, hydroxyacyl-coenzyme A dehydroge-
nase type II, and a protein tyrosine phosphatase (PTP) expressed in 
hematopoietic cells (Table 2).
Because Cdc25B plays a key role(s) in controlling cell cycle pro-
gression, we next examined the ability of the six Cdc25B hits to in-
hibit the proliferation of the human MBA-MD-435 breast and PC-3 
prostate cancer cell lines, both of which express Cdc25B22 (Figs. 3 
and 4). Under the conditions utilized for the assay, both the MBA-
MD-435 breast and PC-3 prostate cancer cell lines are actively prolif-
erating as evidenced by the linear increase in cell counts throughout 
the 72-h time course of the assay (Fig. 3).  Consistent with previous 
reports,22 the three cyclopenta[c]quinoline-carboxylic acid Cdc25B 
inhibitors at 50 μM failed to inhibit the proliferation of either cell 
line (Fig. 4A and B), and the 7-methoxy-3-methyl-1H-indole-2-
carboxylic acid hit (SID 847214) at 50 μM also failed to inhibit the 
growth of either cell line.  However, both of the bis-furan compounds, 
N-[2,3-di(furan-2-yl)quinoxalin-6-yl]azepane-1-carboxamide (SID 
4258795) and  5,6-di(furan-2-yl)-3-(phenylmethylsulfanyl)-1,2,4-
triazine (SID 4260465), inhibited the growth of both cell lines in a 
time- and concentration-dependent manner (Fig. 4).  SID 4258795 
exhibited IC50 values of 96.2 ± 68 μM and 15.3 ± 1.36 µM against 
the MBA-MD-435 and PC-3 cell lines, respectively, while 4260465 
exhibited IC50 values of 50.4 ± 8.6 μM and 47.5 ± 2.75 µM against 
the MBA-MD-435 and PC-3 cell lines, respectively.
To confirm the structure and activity of N-[2,3-di(furan-2-yl)
quinoxalin-6-yl]azepane-1-carboxamide (SID 4260465), the PMLSC 
chemistry core resynthesized the compound (SID 26683752) and two 
analogs (Fig. 5A).  In the 5,6-di(phenyl)-3-(phenylmethylsulfanyl)-
1,2,4-triazine analog (SID 26683753), two phenyl rings were 
substituted for the two furan rings in 26683752, and in the 
5,6-di(furan-2-yl)-3-[2-(2-methoxyethoxy)ethylsulfanyl]-1,2,4-tri-
azine analog (SID 26683756), a 3-(methoxyethoxy)ethylsulfanyl side 
chain was substituted for the 3-phenylmethylsulfanyl side chain in 
SID 26683752.  Only the resynthesized hit SID 26683752 exhibited 
inhibition in the in vitro Cdc25B assay, exhibiting an IC50 of 13.83 
± 1.0 µM (Fig. 5B).  Although both of the analogs (SIDs 26683753 
and 26683756) exhibit partial growth inhibition of both the MBA-
MD-435 breast and PC-3 prostate cancer cell lines at 25 and 50 µM, 
the resynthesized hit (SID 26683752) was significantly more potent 
and produced IC50 values of 20.16 ± 2.0 μM and 24.87 ± 2.25 µM 
against the MBA-MD-435 and PC-3 cell lines, respectively (Fig. 5C 
and D).
Table 2. Cdc25B Inhibitor Specificity: Cross-Target Query of PubChem
PubChem SID
Number of 
assays
Number of 
active flags
Type of flag
Confirmed targetsHTS Confirmation
847214 192 13 5 2 Cdc25B, NFκB
843791 193 19 8 5
Cdc25B, HADH2, HSD17B4, EukTI, 
HePTP
850390 192 18 6 6
Cdc25B, HADH2, HSD17B4, EukTI, 
DNA Pol III, HePTP
851514 206 23 9 8
Cdc25B, HADH2, HSD17B4, EukTI, 
DNA Pol III, Tau, Hsp90, HePTP
4258795 227 37 17 13
Cdc25B, HADH2, HSD17B4, EukTI, 
DNA Pol III, Tau, Hsp90, Cruzain, 
15-hLO, MLVN, Bim-Bfl-1, RT-RNH, 
MKP-1
4260465 211 19 8 7
Cdc25B, HADH2, HSD17B4, Tau, 
Cruzain, 15-hLO, E. coli, HePTP
NFκB, antigen receptor-induced NF-κB activation; HSD17B4, hydroxysteroid 17β-dehydrogenase 4; HADH2, hydroxyacyl-coenzyme A dehydrogenase, type II; EukTI, 
eukaryotic translation initiation; DNA Pol III, DNA polymerase III holoenzyme; Tau, tau filament binding; Hsp90, heat shock protein 90 co-chaperone interaction; Cruzain, 
inhibition of cruzain (the major cysteine protease of Trypanosoma cruzi); 15-hLO, human 15-lipoxygenase; MLVN, mevalonate pathway in Streptococcus pneumoniae; 
E. coli, antimicrobial Escherichia coli BW25113 ?tolC::kan; HePTP, a PTP expressed in hematopoietic cells; Bim-Bfl-1, regulators of Bcl-2 family protein interactions, 
specifically Bim–Bfl-1;  RT-RNH, human immunodeficiency virus type 1 reverse transcriptase associated ribonuclease H.
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DISCUSSION
A significant drug discovery effort has been mounted to find 
Cdc25 inhibitors for cancer thera-
py because of the critical roles that 
these phosphatases have in regulat-
ing cell cycle progression and DNA 
damage-induced checkpoint arrest 
and recovery.1–5  The N-terminal reg-
ulatory domains of the Cdc25s are 
highly divergent but contain multiple 
sequence motifs that modulate their 
catalytic activity, stability, subcellu-
lar localization, and protein–protein 
interactions with partners, regulators, 
and substrates.  These motifs include 
nuclear localization and nuclear ex-
port sequences, 14-3-3 binding sites, 
and multiple sites for phosphorylation 
or ubiquitination.2,5,6  The N-terminal 
regulatory domains of the Cdc25s are 
also subject to alternate splicing that 
generate at least two variants for Cd-
c25A and five each for Cdc25B and 
Cdc25C.2,6  In contrast, the C-terminal 
catalytic domains of the Cdc25s are 
highly conserved (~60% identity) and 
share a common C(X)5R(S/T) active site 
sequence motif with the 107 PTPs of 
the human genome, with X being any 
amino acid,  R an invariant arginine, 
and C the active site cysteine required 
for catalytic activity.2,6,25  The PTP ac-
tive site cysteine performs a nucleo-
philic attack on the phosphotyrosine 
residues of substrates to form covalent 
thiol–phosphate intermediates that are 
then hydrolyzed to release free phos-
phate.2,6,25  The cysteines of PTP active 
sites have a low pKa of 4.7–5.4 and 
exist as thiolate anions at neutral pH, 
which enhances their catalytic activ-
ity as a nucleophile but also makes 
them susceptible to oxidation and 
inactivation.2,6,25  PTP cysteine thio-
lates react with reactive oxygen spe-
cies (ROS) such as H2O2 to produce a 
sulfenic acid form of the enzyme that 
is inactive.15,25–35  PTPs oxidized to the 
sulfenic acid form may be reduced back to the active thiolate species 
by cellular thiol donors such as GSH, but sulfenic acids are highly 
Fig. 3. Human MBA-MD-435 breast and PC-3 prostate cancer cell proliferation assay. (A) Representa-
tive images of MBA-MD-435 cells cultured for 0, 24, 48, and 72 h with and without 100 nM paclitaxel. 
MBA-MD-435 and PC-3 cells were cultured, harvested, seeded, and treated in culture as described in 
Materials and Methods. After a 2-h cell attachment period, one plate of cells was fixed, stained, and 
analyzed as described below to establish the cell density at the time of treatment (T0). The other plates 
were cultured for an additional 24 h, 48 h, or 72 h with or without 100 nM paclitaxel. At the indicated 
time points, plates were fixed and stained with formaldehyde containing 2 µg/ml Hoechst 33342 as 
described in Material and Methods. Images of the Hoechst-stained nuclei from nine fields of view per 
well were acquired on the ArrayScan VTI imaging platform using a 10× 0.3NA objective and the XF100 
filter set. Representative images of a single field of view of Hoechst-stained nuclei from MBA-MD-435 
cells cultured for the indicated times with or without 100 nM paclitaxel are presented. (B and C) Prolif-
eration of (B) MBA-MD-435 and (C) PC-3 cells in culture over a 72-h period with or without 100 nM pa-
clitaxel. Hoechst-stained nuclei from replicate wells (n = 16) were quantified using an image analysis 
algorithm that segmented the images and identified nuclear objects on the basis of total and average 
fluorescent intensity and size (area) and shape (width and length) thresholds. The total number of se-
lected objects (nuclei) from nine fields of view covering the whole well provided the total cell count per 
well. The data are presented as the mean total cell counts per well ± SD of the mean (n = 16) for control 
(?) and 25 nM paclitaxel-treated (?) cells at the indicated time points together with a linear regres-
sion analysis of the data using Graphpad Prism software version 4.03. The r2 correlation coefficients of 
the linear analysis exceeded 0.969 for actively proliferating cells from both cell lines.
A
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reactive and may readily undergo further oxidation to sulfinic and 
sulfonic forms that are irreversibly oxidized and inactive.15,25–35  The 
inactivation of PTPs by the specific and reversible oxidation of the 
active site cysteine by H2O2 has been demonstrated for numerous key 
PTPs that regulate the signaling pathways and networks involved 
in normal physiological processes and disease: PTP1B, PTPα, LAR, 
VHR, PTEN, SHP-2, Cdc25B, 
MKP-3, and MKP-1.15,26–35
The crystal structures of the 
catalytic domains of Cdc25A 
and Cdc25B revealed them to 
be small globular domains with 
a shallow solvent-exposed ac-
tive site and no obvious sites for 
substrate recognition or inhibi-
tor binding.6,36,37  Cdc25–protein 
substrate recognition appears to 
occur through a broad protein–
protein interaction surface,6,36,37 
making the molecular modeling 
of inhibitors exceedingly chal-
lenging and mandating an HTS 
approach.  Almost all of the in 
vitro Cdc25 inhibitors that have 
been described to date were 
identified in assays that em-
ployed the catalytic domains of 
the Cdc25s and small molecule 
substrates.3,19,21,22,38–44  A number 
of potent Cdc25 inhibitors have 
now been synthesized or isolat-
ed from natural product extracts, 
and although many of these ex-
A B
C D
Fig. 4. Time- and concentration-dependent inhibition of (A) MBA-MD-435 and (B) PC-3 cancer cell growth by Cdc25B inhibitors. MBA-MD-435 and 
PC-3 cells were cultured, harvested, seeded, and treated in culture as described in Materials and Methods. After a 2-h cell attachment period, cells 
were treated with DMSO, the indicated Cdc25B inhibitor compounds at 50 μM, or 25 nM paclitaxel, and plates were cultured for an additional 24–72 
h. At the indicated time points, plates were fixed and stained with formaldehyde containing 2 µg/ml Hoechst 33342 as described in Materials and 
Methods. Images of the Hoechst-stained nuclei from nine fields of view per well were acquired on the ArrayScan VTI imaging platform using a 10× 
0.3NA objective and the XF100 filter set. Hoechst-stained nuclei were quantified using an image analysis algorithm to segment the images as de-
scribed in Materials and Methods. The total number of selected objects (nuclei) from nine fields of view covering the whole well provided the total 
cell count per well. The total cell counts observed in compound-treated wells (n = 1) are expressed as a percentage of the mean total cell counts in 
DMSO control wells (n = 16): % of DMSO controls = (total cell count in compound-treated wells × 100)/mean total cell count of DMSO control wells. 
A bar graph of the total cell counts per well of compound-treated wells at 24 h (empty bars), 48 h (cross-hatched bars), and 72 h (solid filled bars) 
expressed as a percentage of DMSO controls is presented. (C and D) Concentration-dependent inhibition of (C) MBA-MD-435 and (D) PC-3 cancer 
cell growth by Cdc25B inhibitors 4258795 and 4260465. MBA-MD-435 and PC-3 cells were cultured, harvested, seeded, and treated in culture as 
described in Materials and Methods. After a 2-h cell attachment period, cells in triplicate wells were treated with the indicated concentrations Cdc25B 
inhibitors 4258795 and 4260465, and plates were cultured for an additional 72 h. Plates were then fixed and stained, and images of the Hoechst 
stained nuclei were acquired and analyzed as described in (A) and (B). The total cell counts observed in compound-treated wells (n = 3) are expressed 
as a percentage of the mean total cell counts in DMSO control wells (n = 16): % of DMSO controls = (total cell count in compound-treated wells × 
100)/mean total cell count of DMSO control wells. The data are presented as the mean percentage of DMSO control cell counts ± SD of the mean (n 
= 3), and the concentration–response data for the effects of the Cdc25B inhibitors 4258795 (?) and 4260465 (?) on MBA-MD-435 (C) and PC-3 (D) 
cell proliferation were fit to curves using the sigmoidal dose–response variable slope equation y = Bottom + (Top – Bottom)/(1 + 10^((LogEC
50
 – x) × 
Hill Slope)), where EC
50
 is the 50% effective concentration, using Graphpad Prism software version 4.03.
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hibit selectivity against other dual-specificity phosphatases or PTPs, 
most inhibit all three Cdc25 isoforms.3,4,10,21,22,38–44  The majority of 
the known Cdc25 inhibitors are quinone-based structures, phosphate 
surrogates, or electrophiles.3,4,10,21,22,38–44  The mechanism of action of 
many quinoid compounds involves the oxidation and inactivation 
of the Cdc25 active site cysteine by 
ROS either generated through in 
vitro redox cycling of these com-
pounds in the presence of DTT or 
induced within cells by exposure 
to these compounds.21,38,45  We have 
previously shown that the in vitro 
inhibition of Cdc25B by cell-active 
quinolinediones was irreversible, 
time dependent, and sensitive to 
pH, CAT, and reducing agents.46,47 
The inhibition of Cdc25B in vitro 
by the quinolinediones required the 
presence of reducing agents and 
was abolished by the addition of 
CAT, implicating the redox cycling 
generation of H2O2 and oxidation 
of the active site cysteine as the 
mode of inhibition.46,47  Exposure 
of cells to quinolinediones direct-
ly triggered the production of in-
tracellular ROS.46  o-Quinone-based 
inhibition of PTPα was shown to be 
time dependent, sensitive to super-
oxide dismutase and CAT, and mediated by the generation of H2O2 
through a cyclic redox mechanism that required both the compound 
and DTT.26  o-Quinones produced H2O2 in the presence of strong re-
ducing agents such as DTT or TCEP but not with weaker reducing 
agents such as GSH or Cys.26  Alternatively, some quinone com-
A B
C D
Fig. 5. Chemical structures, in vitro Cdc25B inhibition, and inhibition of MBA-MD-435 and PC-3 cancer cell growth by Cdc25B inhibitor analogs. 
(A) Chemical structures of the resynthesized Cdc25B inhibitor 4260465 and analogs. The Cdc25B inhibitor hit from the screen SID 4260465 was 
resynthesized by the PMLSC chemistry core along with two analogs. The PubChem SIDs and chemical structures of the resynthesized compound 
SID 26683752 and two analogs, 26683753 (?) and 26683756 (?), are presented. (B) Inhibition of the in vitro Cdc25B activity assay by the re-
synthesized Cdc25B inhibitor hit 26683752 (?) and two analogs. Recombinant Cdc25B enzyme was incubated with 40 µM OMFP in assay buffer 
together with the indicated concentrations of compounds in triplicate wells of a 384-well low-volume microtiter plate for 60 min, and the result-
ing fluorescent intensity at 485 nm excitation/525 nm emission was measured on a SpectraMaxM5 plate reader. An ActivityBase HTS template 
was written to calculate percentage inhibition for each well based on the maximum (2% DMSO, n = 32) and minimum (500 μM Na
3
VO
4
 and 2% 
DMSO) plate controls. The mean percentage inhibition ± SD of triplicate values produced at each compound concentration after the 60-min incu-
bation are plotted together with the resulting nonlinear regression curves plotted using the sigmoidal dose–response variable slope equation y 
= Bottom + (Top – Bottom)/(1 + 10^((LogEC
50
 – x) × Hill Slope)) using Graphpad Prism software version 4.03. (C and D) Concentration-dependent 
inhibition of (C) MBA-MD-435 and (D) PC-3 cancer cell growth by the resynthesized hit 26683752 and two analogs, 26683753 and 26683756. 
MBA-MD-435 and PC-3 cells were seeded in 384-well plates as described in Fig. 4. After a 2-h cell attachment period, cells in triplicate wells were 
treated with the indicated concentrations of compounds, and plates were cultured for an additional 72 h. Images of the fixed and stained cells 
were acquired and analyzed as described in Fig. 4. The total cell counts observed in compound-treated wells (n = 3) are expressed as a percent-
age of the mean total cell counts in DMSO control wells (n = 16): % of DMSO controls = (total cell count in compound-treated wells × 100)/mean 
total cell count of DMSO control wells. The data are presented as the mean percentage of DMSO control cell counts ± SD of the mean (n = 3), and 
the concentration–response data for the effects of the resynthesized hit 26683752 (?) and two analogs, 26683753 (?) and 26683756 (?), on 
(C) MBA-MD-435 and (D) PC-3 cell proliferation were fit to curves using the sigmoidal dose–response variable slope equation y = Bottom + (Top 
– Bottom)/(1+10^((LogEC
50
 – x) × Hill Slope)), where EC
50
 is the 50% effective concentration, using Graphpad Prism software version 4.03.
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pounds have been shown to covalently modify the Cdc25 active site 
cysteines or vicinal serines resulting in inhibition.3,4
The current study describes the first systematic interrogation of a 
large publicly sponsored compound library for inhibitors of in vitro 
Cdc25B activity.  A recently described assay that measures the gen-
eration of H2O2 by redox active compounds in DTT
15 was utilized to 
identify and filter out compounds acting through the oxidation and 
inactivation of the Cdc25 active site cysteine.  Twenty-five compounds 
were subsequently confirmed as concentration-dependent inhibitors of 
Cdc25B activity with IC50 values <50 μM; 13 were represented by sin-
gleton chemical structures, and 12 were divided among four clusters of 
related structures (Fig. 2).  Thirteen (52%) of the 25 Cdc25B inhibitor 
hits have quinone-based structures similar to those previously shown 
to generate ROS (see above): five cyclopenta[c]quinoline-carboxylic 
acids (SIDs 843791, 850390, 844096, 851514, and 4249621), three 
pyrimidotriazine-5,7-diones (SIDs 4251194, 850758, and 845167), two 
isoquinolin-1-ones (SIDs 4251929 and 4249736), one naphthoquinone 
(SID 8139964), one isoquinoline-1,3-dione (SID 7964733), and one 
isoquinolin-5-amine (SID 4248661) (Fig. 2).
The Cdc25B inhibitors were further characterized in a series of in 
vitro secondary assays to identify compounds that might inactivate 
the active site cysteine through oxidation and to evaluate their se-
lectivity for Cdc25B over MKP-1 and MKP-3 dual-specificity phos-
phatases (Table 1).  We incorporated an assay to directly measure 
H2O2 generated by redox cycling compounds in reducing environ-
ments.15  This assay has been used to profile the redox potential of 
MKP-1 inhibitors and a series of p-quinone-based Cdc25B inhibi-
tors.15,45  The conditions of the primary Cdc25B assay were altered to 
determine if the inhibition of Cdc25B would be significantly affected 
by any or all of the following modifications: the strong nonphysi-
ological reducing agent DTT was replaced with the weaker BME or by 
the physiologically relevant GSH; CAT was added to the assay to de-
grade any H2O2 produced; the DTT concentration was increased from 
1 to 25 mM; or reactions were conducted in the presence of both CAT 
and high levels of DTT.  To facilitate the evaluation and analysis of 
the Cdc25B inhibitor hit characteristics we have simplified and sum-
marized the data in Table 1 into an activity profile table (Table 3). 
At least 16 of the hit compounds (SIDs 4242461, 8139964, 856108, 
3712249, 7973677, 845964, 3712327, 847359, 4251194, 845167, 
850758, 857882, 4251929, 4249736, 7964733, and 4248661) inhibit 
Cdc25B activity via the redox cycling generation of ROS, which il-
lustrates the importance of incorporating the assay to measure redox 
cycling H2O2 generation early in the hit characterization process for 
targets susceptible to oxidation.  This conclusion was further sup-
ported by the observation that eight (50%) of the redox active com-
pounds were promiscuous inhibitors of all three phosphatases (Tables 
1 and 3).  The redox cycling generation of H2O2 by the three py-
rimido-triazine-diones (SIDs 850758, 845167, and 4251194) has been 
reported previously,15,48 and a cross-target query of the PubChem da-
tabase revealed that these compounds had produced active flags in 
36–39% of the assays against which they have been screened, and 
their activity has been confirmed for a number of targets with active 
site cysteines  including several PTPs, cathepsins, and caspases.  The 
redox cycling activity and promiscuous inhibition of PTPs by the 
3-amino-7-(phenylmethyl)-1-sulfanylidene-6,8-dihydro-5H-thi-
opyrano[5,4-c]pyridine-4-carbonitrile (SID 845964) have also been 
reported previously.15
Importantly, nine of the Cdc25B hits exhibited a secondary assay 
activity profile consistent with a nonoxidative mechanism of ac-
tion because their inhibition of Cdc25B was resistant to the indicat-
ed modifications to the activity assay (Tables 1 and 3).  Six of the 
nine compounds selectively inhibited Cdc25B over both MKP-1 and 
MKP-3, and a cross-target query of the PubChem database revealed 
that each of the six hits had been tested in ~200 bioassays and that 
their activity had been confirmed against several other targets, in-
cluding a PTP expressed in hematopoietic cells (Table 2).  We next 
examined the ability of the six Cdc25B hits to inhibit the proliferation 
of the human MBA-MD-435 breast and PC-3 prostate cancer cell lines 
(Figs. 3 and 4).  Two of the six hits, N-[2,3-di(furan-2-yl)quinoxalin-
6-yl]azepane-1-carboxamide (SID 4258795) and 5,6-di(furan-2-yl)-
3-(phenylmethylsulfanyl)-1,2,4-triazine (SID 4260465), significantly 
inhibited the growth of both tumor cell lines in a time- and concen-
tration-dependent manner (Figs. 3 and 4).
Interestingly, five of the nine non–redox active Cdc25B hits are 
cyclopentaquinoline carboxylic acid analogs, and three of these 
compounds appear to selectively inhibit Cdc25B (SIDs 843791, 
850390, and 851514) over MKP-1 and MKP-3, whereas two in-
hibit both Cdc25B and MKP-1 but not MKP-3 (SIDs 844096 and 
4249621) (Tables 1 and 3).  Cyclopentaquinoline carboxylic acid 
compounds were previously shown to inhibit Cdc25B activity in 
vitro22 and have more recently been shown to inhibit the activi-
ty of other PTPs, including PTP1B, PTPN5, PTPN7, PTPRR,49 and 
MKP-1.16  Cyclopentaquinoline carboxylic acid analogs have also 
been reported to inhibit both MKP-3 (AID 425) and hematopoi-
etic cell PTP (AID 521) in data uploaded to the PubChem data-
base.  However, consistent with previously published data,22 none 
of the three selective cyclopentaquinoline carboxylic acid Cdc25B 
hits produced significant growth inhibition in either tumor cell line 
(Fig. 4A and B).  The 7-methoxy-3-methyl-1H-indole-2-carboxylic 
acid (SID 847214) Cdc25B hit also failed to inhibit the proliferation 
of either cell line (Fig. 4A and B).
The cell-active Cdc25B inhibitor 4260465 was resynthesized (SID 
26683752) along with two analogs (SIDs 26683753 and 26683756) 
(Fig. 5A).  Neither of the substitutions in the two analogs was tolerated, 
and only the resynthesized hit SID 26683752 inhibited Cdc25B activity 
in vitro (IC50 = 13.83 ± 1.0 µM) and significantly inhibited the growth 
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of the MBA-MD-435 breast and PC-3 prostate cancer cell lines (IC50 = 
20.16 ± 2.0 μM and 24.87 ± 2.25 µM, respectively) (Fig. 5).  The two 
bis-furan-containing hits identified in the screen represent novel non-
oxidative Cdc25B inhibitor chemotypes that inhibit the proliferation of 
cultured tumor cells.  In this context, it is noteworthy to mention the 
known toxicity of furans, which is believed to be due in vivo (mainly) 
or in vitro (less frequently) to the P450-catalyzed oxidation of furan to 
a highly reactive 2-butene-1,4-dial metabolite.50,51  This electrophilic 
metabolite could readily deactivate catalytic or structural sulfhydryl 
groups in Cdc25B or deplete cellular GSH, and the bis-furans may be a 
likely source of reactive metabolites.
Studies have been initiated to further evaluate the cell-based ac-
tivity of these two novel non–redox cycling bis-furan-containing 
Cdc25B inhibitors to determine whether they induce readily detect-
able effects on the cell cycle such as a G1/S or G2/M arrest and 
if they induce hyperphosphorylation of Cdc25B substrates such as 
CDK1.  Positive results will trigger a more extensive chemistry an-
alog synthesis effort to try to enhance the modest potency of these 
Table 3. Cdc25B Inhibitor Activity Profile
SID
Cdc25B HTS % 
inhibition >50%
Cdc25B IC50 <50 
µM
Selective vs. 
MKP-1/3
Redox H2O2 
generator
Cdc25B IC50 
modulated
Inhibition of 
tumor cell 
proliferation
850758 + + — + + NT
845167 + + — + + NT
4251194 + + — + + NT
847359 + + + + + NT
3712327 + + + + + NT
845964 + + — + + NT
7973677 + + — + + NT
3712249 + + — + + NT
856108 + + + + + NT
8139964 + + + + + NT
857882 + + + + + NT
4242461 + + — + + NT
4251929 + + — — + NT
4249736 + + — — + NT
4249621 + + — — — NT
4241893 + + — — — NT
844096 + + — — — NT
850390 + + + — — —
843791 + + + — — —
7964733 + + — — + NT
851514 + + + — — —
847214 + + + — — —
4260465 + + + — — +
4258795 + + + — — +
4248661 + + + — + NT
Cdc25B HTS % inhibition >50%, inhibition >50% in the primary Cdc25B screen; Selective vs. MKP-1/3, selectivity for Cdc25B versus MKP-1 and/or MKP-3; Redox H2O2 
generator, evidence of redox cycling H2O2 generation; Cdc25B IC50 modulated, the inhibition of Cdc25B was sensitive to the modifications in the assay conditions described 
in Table 1; Inhibition of tumor cell proliferation, the ability to inhibit the proliferation of the human MBA-MD-435 breast and PC-3 prostate cancer cell lines. NT = not 
tested. + indicates that the compound met this criterion; — indicates that the compound did not meet this criterion.
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hits and establish a structure–activity relationship.  Despite the large 
number of potent quinoid Cdc25 inhibitors with antiproliferative 
activity against tumor cell lines that are currently available, very 
few of these have demonstrated in vivo activity in human tumor 
cell xenograft animal models.2–4  There are also concerns about the 
potential toxicity of quinonoid compounds in vivo due to the redox 
cycling generation of ROS.2–4  The availability of non–redox active 
Cdc25B inhibitors should provide valuable tools to explore the in-
hibition of the Cdc25 phosphatases as potential mono- or combina-
tion therapies for cancer.
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